Trials / Unknown
UnknownNCT05945394
The Surem TRAF3IP2 Level and Atherosclerotic Plaque Development in Human
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 800 (estimated)
- Sponsor
- Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the association of surem TRAF3IP2 levels with the atherosclerotic plaque development in human
Detailed description
Previous study had concluded that TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability in mice. However, no human data was available. In the present study, patients who receive coronary angiography will be enrolled. Their surem TRAF3IP2 levels will be tested using ELASA. The association of surem TRAF3IP2 levels with the atherosclerotic plaque will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | This is an obvertional study, and there is no intervention. |
Timeline
- Start date
- 2023-09-01
- Primary completion
- 2023-10-31
- Completion
- 2023-12-31
- First posted
- 2023-07-14
- Last updated
- 2023-09-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05945394. Inclusion in this directory is not an endorsement.